Total Payments
$228,244
2024 Payments
$584.02
Companies
22
Transactions
472
Medicare Patients
11,745
Medicare Billing
$7.8M
Payment Breakdown by Category
Other$178,078 (78.0%)
Travel$22,387 (9.8%)
Consulting$17,400 (7.6%)
Food & Beverage$10,300 (4.5%)
Education$80.46 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $174,688 | 97 | 76.5% |
| Travel and Lodging | $22,387 | 110 | 9.8% |
| Consulting Fee | $17,400 | 6 | 7.6% |
| Food and Beverage | $10,300 | 253 | 4.5% |
| Honoraria | $3,390 | 1 | 1.5% |
| Education | $80.46 | 5 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $122,060 | 205 | $0 (2024) |
| Lilly USA, LLC | $65,389 | 97 | $0 (2024) |
| Radius Health, Inc. | $31,131 | 60 | $0 (2023) |
| Aurinia Pharma U.S., Inc. | $3,745 | 5 | $0 (2022) |
| UCB, Inc. | $2,731 | 8 | $0 (2024) |
| ABBVIE INC. | $464.58 | 10 | $0 (2023) |
| Genentech USA, Inc. | $428.72 | 29 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $362.07 | 4 | $0 (2024) |
| PFIZER INC. | $319.74 | 9 | $0 (2020) |
| GENZYME CORPORATION | $317.95 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $584.02 | 8 | Amgen Inc. ($261.87) |
| 2023 | $5,756 | 14 | Lilly USA, LLC ($5,188) |
| 2022 | $24,884 | 43 | Lilly USA, LLC ($20,757) |
| 2021 | $18,733 | 19 | Lilly USA, LLC ($15,876) |
| 2020 | $24,159 | 48 | Lilly USA, LLC ($23,393) |
| 2019 | $35,300 | 84 | Amgen Inc. ($32,141) |
| 2018 | $63,658 | 159 | Amgen Inc. ($31,638) |
| 2017 | $55,170 | 97 | Amgen Inc. ($54,602) |
All Payment Transactions
472 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $55.56 | General |
| Category: Immunology | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 07/26/2024 | Organon Llc | RENFLEXIS (Drug), HADLIMA | Food and Beverage | In-kind items and services | $7.38 | General |
| Category: INFLIXIMAB | ||||||
| 05/30/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Inflammation | ||||||
| 05/09/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $111.24 | General |
| Category: Rheumatology | ||||||
| 04/10/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: Inflammation | ||||||
| 03/27/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: Bone Health | ||||||
| 01/27/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $26.14 | General |
| Category: Immunology | ||||||
| 12/15/2023 | Organon LLC | RENFLEXIS (Drug), HADLIMA | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: INFLIXIMAB | ||||||
| 11/17/2023 | Organon LLC | RENFLEXIS (Drug), HADLIMA | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: INFLIXIMAB | ||||||
| 11/13/2023 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $86.84 | General |
| Category: Endocrinology | ||||||
| 11/09/2023 | Radius Health, Inc. | Tymlos (Drug) | Education | In-kind items and services | $47.40 | General |
| Category: Endocrinology | ||||||
| 09/29/2023 | Radius Health, Inc. | Tymlos (Drug) | Education | In-kind items and services | $3.16 | General |
| Category: Endocrinology | ||||||
| 09/13/2023 | Organon LLC | RENFLEXIS (Drug), HADLIMA | Food and Beverage | In-kind items and services | $11.84 | General |
| Category: INFLIXIMAB | ||||||
| 07/19/2023 | Organon LLC | HADLIMA (Drug) | Food and Beverage | In-kind items and services | $11.46 | General |
| Category: ADALIMUMAB-BWWD | ||||||
| 03/30/2023 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: IMMUNOLOGY | ||||||
| 03/16/2023 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: Inflammation | ||||||
| 03/06/2023 | Lilly USA, LLC | TALTZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| Category: Immunology | ||||||
| 03/06/2023 | Lilly USA, LLC | TALTZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $875.00 | General |
| Category: Immunology | ||||||
| 03/01/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $109.98 | General |
| Category: IMMUNOLOGY | ||||||
| 02/23/2023 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Bone Health | ||||||
| 02/06/2023 | Lilly USA, LLC | TALTZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,012.50 | General |
| Category: Immunology | ||||||
| 11/15/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | Cash or cash equivalent | $147.50 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/03/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Honoraria | Cash or cash equivalent | $3,390.00 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 10/29/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $100.71 | General |
| Category: LUPUS NEPHRITIS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 2,837 | 122,701 | $4.5M | $1.9M |
| 2022 | 26 | 3,000 | 106,488 | $4.1M | $1.8M |
| 2021 | 25 | 2,976 | 119,646 | $4.8M | $2.2M |
| 2020 | 25 | 2,932 | 92,305 | $4.3M | $2.0M |
Total Patients
11,745
Total Services
441,140
Medicare Billing
$7.8M
Procedure Codes
99
All Medicare Procedures & Services
99 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 482 | 40,920 | $1.4M | $747,759 | 52.2% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 61 | 12,825 | $884,925 | $431,806 | 48.8% |
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 15 | 2,200 | $308,000 | $139,325 | 45.2% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 19 | 24,650 | $172,550 | $115,685 | 67.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 767 | 1,248 | $187,200 | $113,742 | 60.8% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 21 | 28,800 | $345,600 | $112,726 | 32.6% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 40 | 4,090 | $613,500 | $106,763 | 17.4% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 16 | 5,350 | $214,000 | $56,769 | 26.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 154 | 409 | $108,385 | $41,248 | 38.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 219 | 253 | $25,806 | $16,368 | 63.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 21 | 144 | $20,880 | $8,087 | 38.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 488 | 692 | $24,220 | $7,579 | 31.3% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 202 | 202 | $27,674 | $7,452 | 26.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 56 | 183 | $13,725 | $3,995 | 29.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 30 | $6,030 | $3,832 | 63.5% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 46 | 66 | $8,736 | $3,321 | 38.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $6,237 | $2,925 | 46.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 39 | 39 | $10,335 | $1,829 | 17.7% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 39 | 195 | $48,750 | $1,226 | 2.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 15 | 19 | $1,368 | $746.64 | 54.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 16 | 30 | $1,140 | $358.77 | 31.5% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 52 | 305 | $1,220 | $235.97 | 19.3% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 15 | 24 | $168.00 | $102.06 | 60.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 476 | 39,000 | $1.4M | $664,881 | 48.7% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 53 | 10,375 | $715,875 | $359,918 | 50.3% |
About Dr. Michael Maricic, MD
Dr. Michael Maricic, MD is a Rheumatology healthcare provider based in Tucson, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720179971.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Maricic, MD has received a total of $228,244 in payments from pharmaceutical and medical device companies, with $584.02 received in 2024. These payments were reported across 472 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($174,688).
As a Medicare-enrolled provider, Maricic has provided services to 11,745 Medicare beneficiaries, totaling 441,140 services with total Medicare billing of $7.8M. Data is available for 4 years (2020–2023), covering 99 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Tucson, AZ
- Active Since 09/27/2006
- Last Updated 04/07/2010
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1720179971
Products in Payments
- Prolia (Biological) $88,868
- TALTZ (Drug) $58,017
- Tymlos (Biological) $30,993
- EVENITY (Biological) $10,579
- LUPKYNIS (Drug) $3,745
- SAPHNELO (Biological) $362.07
- TAVNEOS (Drug) $246.83
- Rituxan (Biological) $215.97
- KEVZARA (Drug) $189.99
- Enbrel (Biological) $186.63
- BENLYSTA (Biological) $180.90
- XELJANZ (Drug) $172.07
- Actemra (Biological) $155.06
- Tymlos (Drug) $137.40
- SKYRIZI (Biological) $131.27
- Rinvoq (Biological) $125.23
- NUCALA (Biological) $125.00
- TREMFYA (Drug) $124.98
- RINVOQ (Drug) $122.27
- EMBEDA (Drug) $118.06
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Tucson
Berchman Vaz, Md, MD
Rheumatology — Payments: $62,069
Rheumatology $62,069
Jeffrey Loomer, Md, MD
Rheumatology — Payments: $34,706
Rheumatology $34,706
Ulker Tok, M.d, M.D
Rheumatology — Payments: $24,109
Rheumatology $24,109
Dr. Dominick Sudano, M.d, M.D
Rheumatology — Payments: $17,897
Rheumatology $17,897
Jawad Bilal, M.d, M.D
Rheumatology — Payments: $10,862
Rheumatology $10,862
Dr. Ernest Vina, Md, MD
Rheumatology — Payments: $6,432
Rheumatology $6,432